Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations by Choudhary, GS, Pellagatti, A, Agianian, B, Smith, MA, Bhagat, TD, Gordon-Mitchell, S, Sahu, S, Pandey, S, Shah, N, Aluri, S, Aggarwal, R, Aminov, S, Schwartz, L, Steeples, V, Booher, RN, Ramachandra, M, Samson, M, Carbajal, M, Pradhan, K, Bowman, TV, Pillai, MM, Will, B, Wickrema, A, Shastri, A, Bradley, RK, Martell, RE, Steidl, UG, Gavathiotis, E, Boultwood, J, Starczynowski, DT, Verma, A

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine by Rahmani, NE, Ramachandra, N, Sahu, S, Gitego, N, Lopez, A, Pradhan, K, Bhagat, TD, Gordon-Mitchell, S, Pena, BR, Kazemi, M, Rao, K, Giricz, O, Maqbool, SB, Olea, R, Zhao, Y, Zhang, J, Dolatshad, H, Tittrea, V, Tatwavedi, D, Singh, S, Lee, J, Sun, T, Steidl, U, Shastri, A, Inoue, D, Abdel-Wahab, O, Pellagatti, A, Gavathiotis, E, Boultwood, J, Verma, A

Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells by Shastri, A, Choudhary, G, Teixeira, M, Gordon-Mitchell, S, Ramachandra, N, Bernard, L, Bhattacharyya, S, Lopez, R, Pradhan, K, Giricz, O, Ravipati, G, Wong, L, Cole, S, Bhagat, T, Feld, J, Dhar, Y, Bartenstein, M, Thiruthuvanathan, V, Wickrema, A, Ye, B, Frank, D, Pellagatti, A, Boultwood, J, Zhou, T, Kim, Y, Macleod, A, Epling-Burnette, P, Ye, M, McCoon, P, Woessner, R, Steidl, U, Will, B, Verma, A